Description: PharmaEngine, Inc., a biopharmaceutical company, engages in the development of drugs and therapeutic drugs for treating cancer in Taiwan and Europe. It is developing ONIVYDE, a proprietary liposome encapsulation of irinotecan, a topoisomerase 1 inhibitor for the treatment of metastatic pancreatic cancer; PEP06, which is in Phase I clinical trial for the treatment of cancer; and PEP07, a Chk1 inhibitor, which is in preclinical development stage to accumulate DNA damage in cells, lead to replication catastrophe, and induce cell apoptosis. PharmaEngine, Inc. was incorporated in 2002 and is headquartered in Taipei, Taiwan.
Home Page: www.pharmaengine.com
10 Minsheng East Road
Taipei,
104
Taiwan
Phone:
886 2 2515 8228
Officers
| Name | Title |
|---|---|
| Mr. Hong-Ren Wang Ph.D. | Pres & CEO |
| Jose Hsieh | Sr. Mang. of Accounting |
| Mr. Chi-Hsing Chang | VP of Corp. Devel. |
| Mr. Peter Wu | Sr. Director of Marketing & Sales |
| Melody Lin | Director of HR |
| Dr. C. Hubert Chan M.D., Ph.D. | VP of Clinical & Regulatory Affairs |
Exchange: TWO
Country: TW
Currency: New Taiwan Dollar (NT$)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 44.6565 |
| Price-to-Book MRQ: | 4.7242 |
| Price-to-Sales TTM: | 24.1287 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |